William Sandborn
Expertise in
15
conditions

Dr. William Sandborn

Gastroenterology
Office
9350 Campus Point Dr Ste 2B, 
La Jolla, CA 
Expertise in
15
conditions
Office
9350 Campus Point Dr Ste 2B, 
La Jolla, CA 

Overview

William Sandborn is a Gastroenterologist in La Jolla, California. Dr. Sandborn is highly rated in 15 conditions, according to our data. His top areas of expertise are Crohn's Disease, Hemorrhagic Proctocolitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 583 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Office
9350 Campus Point Dr Ste 2B, La Jolla, CA 92037
Other Locations
UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, La Jolla, CA 92093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
Enrollment Status: Terminated
Publish Date: January 04, 2022
Intervention Type: Drug
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials

583 Total Publications

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Journal: Journal of Crohn's & colitis
Published: April 17, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Rena Yadlapati
Gastroenterology
Expertise in
13
conditions
Dr. Rena Yadlapati
Gastroenterology

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (9.2 miles away)
619-543-2347
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rena Yadlapati is a Gastroenterologist in La Jolla, California. Dr. Yadlapati is highly rated in 13 conditions, according to our data. Her top areas of expertise are Gastroesophageal Reflux Disease (GERD), Achalasia, Heartburn, Endoscopy, and Colonoscopy.

Brigid Boland
Expertise in
9
conditions
Dr. Brigid Boland
Gastroenterology
Expertise in
9
conditions
Dr. Brigid Boland
Gastroenterology

UC San Diego Student Health SVC Pharmacy

9500 Gilman Dr, 
La Jolla, CA 
 (9.3 miles away)
858-534-3300
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brigid Boland is a Gastroenterologist in La Jolla, California. Dr. Boland has been practicing medicine for over 18 years is highly rated in 9 conditions, according to our data. Her top areas of expertise are Ulcerative Colitis, Crohn's Disease, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

Expertise in
9
conditions
Dr. Ravinder Mittal
Gastroenterology
Expertise in
9
conditions
Dr. Ravinder Mittal
Gastroenterology

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (9.2 miles away)
619-543-6834
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravinder Mittal is a Gastroenterologist in La Jolla, California. Dr. Mittal is highly rated in 9 conditions, according to our data. His top areas of expertise are Achalasia, Bowel Incontinence, Swallowing Difficulty, and Gastroesophageal Reflux Disease (GERD).

Frequently Asked Questions about Dr. William Sandborn

How do I make an appointment with Dr. William Sandborn?

You can book an appointment with Dr. William Sandborn by calling their office at 619-543-2347. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William Sandborn a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William Sandborn is classified as an Elite expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William Sandborn specialize in?

While Dr. William Sandborn is a Gastroenterology, they have specific expertise in Crohn's Disease, Hemorrhagic Proctocolitis, and Ulcerative Colitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. William Sandborn participate in research or clinical trials?

Yes. Dr. William Sandborn has published 583 articles and abstracts on conditions like Crohn's Disease. You can view a list of Dr. William Sandborn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. William Sandborn accept my insurance?

Dr. William Sandborn accepts most major insurance plans, including Humana. We recommend calling the office directly at 619-543-2347 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sandborn's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 7 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile